COVID-19 in India
India's Delta-driven second wave of 2021 was one of the worst COVID catastrophes globally — with a true death toll potentially exceeding 4 million — followed by a massive vaccination effort.
Pandemic Overview
| Metric | Data |
| Official cases | >45 million |
| Official deaths | ~533,000 |
| Estimated excess deaths | 4–7 million (Lancet/Economist estimates) |
| Vaccine doses administered | >2.2 billion |
| Peak daily cases (2nd wave) | ~414,000 (May 6, 2021) |
The Catastrophic Second Wave (April–May 2021)
India's second wave, driven by the Delta variant (B.1.617.2 — which originated in India), was one of the worst COVID humanitarian disasters. Daily cases peaked at 414,000; true daily infections were likely millions. Hospitals overflowed; patients waited in ambulances, parking lots, and temple courtyards. Oxygen concentrators ran out nationally — states competed for supply. Crematoriums burned 24 hours a day; overflowing, they moved to parks. Bodies floated down the Ganges.
A Lancet study published in 2022 estimated that India's COVID excess mortality was 4.07 million — approximately 7.5x the official count. The gap reflects limited testing in rural areas, death certificate attribution issues, overwhelmed civil registration systems, and possible political factors in reporting.
India's Vaccination Campaign
Despite the pandemic crisis, India launched one of the largest vaccination campaigns in history — administering over 2.2 billion doses as of 2023. Vaccines used:
- CoviShield (Serum Institute / AstraZeneca): primary vaccine used in the rollout
- Covaxin (Bharat Biotech): India's first indigenously developed COVID vaccine (inactivated virus), globally significant as proof of low-income country vaccine R&D capacity
- Corbevax (Biological E): protein subunit vaccine for adolescents
- Covovax (Serum/Novavax): for adults requiring non-mRNA option
India also donated CoviShield to neighboring countries and African nations through the Vaccine Maitri (Vaccine Friendship) initiative — halted during the second wave when domestic demand overwhelmed supply, but resumed later.
Get COVID Outbreak Alerts
FAQ
Official deaths: ~533,000. Excess mortality analyses estimate 4–7 million excess deaths during the pandemic. The gap reflects underreporting, limited rural testing, and attribution challenges. India disputed the Lancet's 4.07 million estimate.
Yes. Covaxin (Bharat Biotech) is an inactivated SARS-CoV-2 vaccine developed entirely in India. It received WHO Emergency Use Listing in November 2021. It is clinically significant as the first inactivated COVID vaccine developed by a low-middle-income country.
Sources: India Ministry of Health COVID dashboard; Lancet India excess mortality study (Jha et al. 2022); The Economist excess mortality model; ICMR Covaxin trial data.
Related: COVID-19 overview · USA COVID · 2020 COVID first wave